RU2000131681A - Triterpene compositions and methods for their use - Google Patents

Triterpene compositions and methods for their use

Info

Publication number
RU2000131681A
RU2000131681A RU2000131681/14A RU2000131681A RU2000131681A RU 2000131681 A RU2000131681 A RU 2000131681A RU 2000131681/14 A RU2000131681/14 A RU 2000131681/14A RU 2000131681 A RU2000131681 A RU 2000131681A RU 2000131681 A RU2000131681 A RU 2000131681A
Authority
RU
Russia
Prior art keywords
cell
triterpene
composition according
composition
acacia victoriae
Prior art date
Application number
RU2000131681/14A
Other languages
Russian (ru)
Other versions
RU2244547C2 (en
Inventor
Чарльз Дж. АРНТЗЕН
Блейк МЭРИ
Джордан У. ГУТТЕРМАН
Джозеф Дж. ХОФФМАНН
Дэвид Т. БЕЙЛИ
Гамини С. ДЖЕЙАТИЛЕЙК
Original Assignee
Рисерч Дивелопмент Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рисерч Дивелопмент Фаундейшн filed Critical Рисерч Дивелопмент Фаундейшн
Publication of RU2000131681A publication Critical patent/RU2000131681A/en
Application granted granted Critical
Publication of RU2244547C2 publication Critical patent/RU2244547C2/en

Links

Claims (1)

1. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae; b) содержанием, по крайней мере, одного тритерпенового гликозида, имеющего молекулярную массу от примерно 1800 до примерно 2600; c) способностью индуцировать цитотоксичность клетки Jurkat и d) способностью индуцировать апоптоз клетки Jurkat.1. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues; b) the content of at least one triterpene glycoside having a molecular weight of from about 1800 to about 2600; c) the ability to induce cytotoxicity of Jurkat cells; and d) the ability to induce apoptosis of Jurkat cells. 2. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae; b) содержанием, по крайней мере, одного тритерпенового гликозида, имеющего молекулярную массу от примерно 1800 до примерно 2600 и c) способностью индуцировать высвобождение цитохрома-с из митохондрий клетки Jurkat.2. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues; b) the content of at least one triterpene glycoside having a molecular weight of from about 1800 to about 2600; and c) the ability to induce the release of cytochrome c from mitochondria of a Jurkat cell. 3. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae; b) содержанием, по крайней мере, одного тритерпенового гликозида, имеющего молекулярную массу от примерно 1800 до примерно 2600 и c) способностью активировать каспазу-3 в клетке Jurkat.3. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues; b) the content of at least one triterpene glycoside having a molecular weight of from about 1800 to about 2600; and c) the ability to activate caspase-3 in a Jurkat cell. 4. Смесь по п.3, где активность указанной каспазы составляет от примерно 0,3 до примерно 1,6 единиц флуоресценции в минуту на 1 мг.4. The mixture according to claim 3, where the activity of the specified caspase is from about 0.3 to about 1.6 units of fluorescence per minute per 1 mg. 5. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae; b) содержанием, по крайней мере, одного тритерпенового гликозида, имеющего молекулярную массу от примерно 1800 до примерно 2600 и c) способностью вызывать расщепление PARP в клетке Jurkat.5. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues; b) the content of at least one triterpene glycoside having a molecular weight of from about 1800 to about 2600; and c) the ability to cause PARP cleavage in a Jurkat cell. 6. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae; b) содержанием, по крайней мере, одного тритерпенового гликозида, имеющего молекулярную массу от примерно 1800 до примерно 2600 а.е.м. и c) способностью ингибировать активность киназы PI-3 в клетке Jurkat.6. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues; b) the content of at least one triterpene glycoside having a molecular weight of from about 1800 to about 2600 amu and c) the ability to inhibit PI-3 kinase activity in a Jurkat cell. 7. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae и b) способностью ингибировать инициацию и активацию эпителиальных клеток млекопитающего в предзлокачественном или злокачественном состоянии.7. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues and b) the ability to inhibit the initiation and activation of mammalian epithelial cells in a precancerous or malignant state. 8. Смесь, содержащая один или несколько выделенных тритерпеновых гликозидов, отличающаяся следующими свойствами: a) выделяемостью из тканей Acacia victoriae и b) способностью индуцировать апоптоз злокачественных клеток млекопитающих.8. A mixture containing one or more isolated triterpene glycosides, characterized by the following properties: a) secreted from Acacia victoriae tissues and b) the ability to induce apoptosis of mammalian malignant cells. 9. Нутрицевтическая композиция, содержащая смесь по любому из пп.1-12 в фармакологически приемлемой среде.9. Nutraceutical composition containing the mixture according to any one of claims 1 to 12 in a pharmacologically acceptable medium. 10. Нутрицевтическая композиция, содержащая высушенные и измельченные корни или бобы Acacia victoriae в фармакологически приемлемой среде.10. Nutraceutical composition containing dried and ground Acacia victoriae roots or beans in a pharmacologically acceptable medium. 11. Нутрицевтическая композиция по п.10, где указанной фармакологически приемлемой средой является буфер, растворитель, разбавитель, инертный носитель, масло, крем или годный в пищу материал.11. The nutraceutical composition of claim 10, wherein said pharmacologically acceptable medium is a buffer, diluent, diluent, inert carrier, oil, cream, or edible material. 12. Способ получения композиции, содержащей смесь из одного или нескольких тритерпеновых гликозидов, включающий: a) получение ткани из растения Acacia victoriae; b) экстракцию указанной ткани растворителем и c) получение одного или нескольких тритерпеновых гликозидов.12. A method of obtaining a composition containing a mixture of one or more triterpene glycosides, comprising: a) obtaining tissue from an Acacia victoriae plant; b) extracting said tissue with a solvent; and c) obtaining one or more triterpene glycosides. 13. Способ получения композиции выделенных тритерпеновых гликозидов, включающий: a) приготовление тканевой культуры, включающей клетки растения Acacia victoriae и b) экстракцию указанной композиции тритерпеновых гликозидов из указанной культуры растворителем, тем самым экстрагируя, по крайней мере, первое тритерпеновое гликозидное соединение.13. A method of obtaining a composition of isolated triterpene glycosides, comprising: a) preparing a tissue culture comprising Acacia victoriae plant cells; and b) extracting said triterpene glycoside composition from said culture with a solvent, thereby extracting at least the first triterpene glycoside compound. 14. Тритерпеновый гликозид, полученный любым способом по пп.12 и 13.14. Triterpene glycoside obtained by any method according to claims 12 and 13. 15. Тканевая культура волосовидных корней, включающая клетки растения Acacia victoriae, которые были инфицированы Agrobacterium rhizogenes R1000, в культуральной среде.15. Tissue culture of hairy roots, including cells of the Acacia victoriae plant that were infected with Agrobacterium rhizogenes R1000, in a culture medium. 16. Тканевая культура по п.15, где указанная культуральная среда содержит от примерно 3 до примерно 4% сахарозы по массе.16. The tissue culture of claim 15, wherein said culture medium contains from about 3 to about 4% sucrose by weight. 17. Способ непрерывного сбора ткани растения Acacia victoriae, включающий: a) выращивание растения Acacia victoriae методом гидропоники и b) сбор указанной ткани из указанного растения от примерно одного до примерно четырех раз в год, причем указанный сбор не приводит к гибели указанного растения.17. A method for continuously collecting Acacia victoriae plant tissue, comprising: a) hydroponic Acacia victoriae plant cultivation and b) collecting said tissue from said plant from about one to about four times a year, said collection not killing said plant. 18. Способ по п.17, где указанной системой выращивания является аэропоника.18. The method of claim 17, wherein said growing system is aeroponics. 19. Композиция, включающая тритерпеновую составляющую, присоединенную к монотерпеновой составляющей, имеющая формулу:19. A composition comprising a triterpene component attached to a monoterpene component having the formula:
Figure 00000001
Figure 00000001
 или ее фармацевтический препарат,or its pharmaceutical preparation, где R1 и R2 выбирают из группы, состоящей из водорода, C1-5-алкила и олигосахарида;where R 1 and R 2 are selected from the group consisting of hydrogen, C 1-5 alkyl and oligosaccharide; R3 выбирают из группы, состоящей из водорода, гидроксила, C1-5-алкила, C1-5-алкилена, C1-5-алкилкарбонила, сахара и монотерпеновой группы,R 3 is selected from the group consisting of hydrogen, hydroxyl, C 1-5 alkyl, C 1-5 alkylene, C 1-5 alkylcarbonyl, sugar and a monoterpene group, формула дополнительно включает R4, где R4 выбирают из группы, состоящей из водорода, гидроксила, C1-5-алкила, C1-5-алкилена, C1-5-алкилкарбонила, сахара, C1-5-алкилового сложного эфира и монотерпеновой группы, и где R4 может быть присоединен к тритерпеновой составляющей или монотерпеновой составляющей.the formula further includes R 4 , where R 4 is selected from the group consisting of hydrogen, hydroxyl, C 1-5 alkyl, C 1-5 alkylene, C 1-5 alkylcarbonyl, sugar, C 1-5 alkyl ester and a monoterpene group, and where R 4 can be attached to a triterpene component or a monoterpene component. 20. Композиция по п.19, дополнительно включающая монотерпеновую составляющую, связанную с сахаром.20. The composition according to claim 19, further comprising a monoterpene component associated with sugar. 21. Композиция по п.20, где R3 имеет формулу21. The composition according to claim 20, where R 3 has the formula
Figure 00000002
Figure 00000002
 в которой R5 выбирают из группы, состоящей из водорода, гидроксила, C1-5-алкила, C1-5-алкилена, C1-5-алкилкарбонила, сахара, C1-5-алкилового сложного эфира и монотерпеновой группы.in which R 5 is selected from the group consisting of hydrogen, hydroxyl, C 1-5 alkyl, C 1-5 alkylene, C 1-5 alkylcarbonyl, sugar, C 1-5 alkyl ester and a monoterpene group. 22. Композиция по п.19, включающая тритерпеновый гликозид молекулярной формулы22. The composition according to claim 19, including triterpene glycoside of the molecular formula
Figure 00000003
Figure 00000003
 или ее фармацевтический препарат,or its pharmaceutical preparation, где R1 представляет олигосахарид, включающий N-ацетилглюкозамин, фукозу и ксилозу;where R 1 represents an oligosaccharide comprising N-acetylglucosamine, fucose and xylose; R2 представляет олигосахарид, включающий глюкозу, арабинозу и рамнозу.R 2 represents an oligosaccharide comprising glucose, arabinose and rhamnose. 23. Композиция по п.22, имеющая молекулярную формулу23. The composition according to item 22, having the molecular formula
Figure 00000004
Figure 00000004
 или ее фармацевтический препарат.or its pharmaceutical preparation. 24. Композиция по п.19, включающая тритерпеновый гликозид молекулярной формулы24. The composition according to claim 19, including triterpene glycoside of the molecular formula
Figure 00000005
Figure 00000005
 или ее фармацевтический препарат,or its pharmaceutical preparation, где R1 представляет олигосахарид, включающий N-ацетилглюкозамин, фукозу и ксилозу;where R 1 represents an oligosaccharide comprising N-acetylglucosamine, fucose and xylose; R2 представляет олигосахарид, включающий глюкозу, арабинозу и рамнозу.R 2 represents an oligosaccharide comprising glucose, arabinose and rhamnose. Композиция по п.24, имеющая молекулярную формулуThe composition according to paragraph 24, having a molecular formula
Figure 00000006
Figure 00000006
 или ее фармацевтический препарат.or its pharmaceutical preparation. 26. Композиция по п.19, включающая тритерпеновый гликозид молекулярной формулы26. The composition according to claim 19, including triterpene glycoside of the molecular formula
Figure 00000007
Figure 00000007
 или ее фармацевтический препарат,or its pharmaceutical preparation, где R1 представляет олигосахарид, включающий N-ацетилглюкозамин, глюкозу, фукозу и ксилозу;where R 1 represents an oligosaccharide comprising N-acetylglucosamine, glucose, fucose and xylose; R2 представляет олигосахарид, включающий глюкозу, арабинозу и рамнозу.R 2 represents an oligosaccharide comprising glucose, arabinose and rhamnose. 27. Композиция по п.26, имеющая молекулярную формулу:27. The composition according to p. 26, having the molecular formula:
Figure 00000008
Figure 00000008
 28. Композиция по п.19, включающая тритерпеновую оставляющую, олигосахарид и три монотерпеновых звена.28. The composition according to claim 19, including triterpene leaving, oligosaccharide and three monoterpene links. 29. Композиция по п.28, в которой тритерпеновая составляющая является акациевой кислотой или олеаноловой кислотой.29. The composition of claim 28, wherein the triterpene moiety is acacic acid or oleanolic acid. 30. Фармацевтическая композиция, содержащая композицию по любому из пп.19-29 в фармацевтически приемлемой среде.30. A pharmaceutical composition comprising a composition according to any one of claims 19-29 in a pharmaceutically acceptable medium. 31. Композиция по любому из пп.19-29, используемая для производства лекарственного препарата для ингибирования инициации и активации эпителиальной клетки млекопитающего в предзлокачественном или злокачественном состоянии у млекопитающего.31. The composition according to any one of paragraphs.19-29, used for the manufacture of a medicament for inhibiting the initiation and activation of a mammalian epithelial cell in a precancerous or malignant state in a mammal. 32. Композиция по любому из пп.19-29, используемая для производства лекарственного препарата для стимулирования апоптоза злокачественной клетки млекопитающего.32. The composition according to any one of paragraphs.19-29, used for the manufacture of a medicament for stimulating apoptosis of a malignant mammalian cell. 33. Композиция по любому из пп.19-29, используемая для производства лекарственного препарата для предотвращения аномальной пролиферации эпителиальной клетки млекопитающего.33. The composition according to any one of paragraphs.19-29, used for the manufacture of a medicament for preventing abnormal proliferation of mammalian epithelial cells. 34. Композиция по любому из пп.19-29, используемая для производства лекарственного препарата для лечения воспаления у млекопитающего.34. The composition according to any one of paragraphs.19-29, used for the manufacture of a medicinal product for the treatment of inflammation in a mammal. 35. Композиция по любому из пп.19-29, используемая для производства лекарственного препарата для регуляции ангиогенеза у млекопитающего.35. The composition according to any one of paragraphs.19-29, used for the manufacture of a medicinal product for the regulation of angiogenesis in a mammal. 36. Способ стимулирования высвобождения цитохрома-с из митохондрий клетки млекопитающего, включающий введение указанному млекопитающему терапевтически эффективного количества фармацевтической композиции по п.30.36. A method of stimulating the release of cytochrome c from mitochondria of a mammalian cell, comprising administering to said mammal a therapeutically effective amount of a pharmaceutical composition according to claim 30. 37. Способ по п.36, где указанным млекопитающим является человек.37. The method according to clause 36, where the specified mammal is a human. 38. Способ по п.36, где указанной клеткой млекопитающего является злокачественная клетка.38. The method according to clause 36, where the specified mammalian cell is a malignant cell. 39. Способ по п.38, где клеткой является клетка кожи, клетка толстой кишки, клетка матки, клетка яичника, клетка поджелудочной железы, клетка предстательной железы, клетка почки, клетка легкого, клетка мочевого пузыря, эпителиальная клетка или клетка молочной железы.39. The method of claim 38, wherein the cell is a skin cell, colon cell, uterine cell, ovarian cell, pancreatic cell, prostate cell, kidney cell, lung cell, bladder cell, epithelial cell or breast cell. 40. Способ по п.36, где указанное введение осуществляют перорально.40. The method according to clause 36, where the specified introduction is carried out orally. 41. Способ по п.36, где указанное введение осуществляют местно.41. The method according to clause 36, where the specified introduction is carried out locally. 42. Способ по п.36, где указанное введение осуществляют путем внутриопухолевой инъекции.42. The method according to clause 36, where the specified introduction is carried out by intratumoral injection. 43. Способ по п.36, где указанное введение осуществляют внутривенно.43. The method according to clause 36, where the specified introduction is carried out intravenously. 44. Способ по п.36, где указанное введение осуществляют путем ингаляции аэрозолем.44. The method according to clause 36, where the specified introduction is carried out by inhalation with an aerosol. 45. Способ по п.36, дополнительно включающий облучение указанной эпителиальной клетки.45. The method according to clause 36, further comprising irradiating the specified epithelial cell. 46. Способ по п.45, где указанную клетку облучают рентгеновским излучением, УФ-излучением, γ-излучением или микроволновым излучением.46. The method according to item 45, where the specified cell is irradiated with x-ray radiation, UV radiation, γ-radiation or microwave radiation.
RU2000131681/15A 1998-05-19 1999-05-19 Triterpene compositions and methods for their applying RU2244547C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8599798P 1998-05-19 1998-05-19
US60/085,997 1998-05-19
US9906698P 1998-09-03 1998-09-03
US60/099,066 1998-09-03

Publications (2)

Publication Number Publication Date
RU2000131681A true RU2000131681A (en) 2003-06-27
RU2244547C2 RU2244547C2 (en) 2005-01-20

Family

ID=26773317

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000131681/15A RU2244547C2 (en) 1998-05-19 1999-05-19 Triterpene compositions and methods for their applying

Country Status (13)

Country Link
US (8) US6444233B1 (en)
EP (1) EP1079824B1 (en)
JP (1) JP4860039B2 (en)
KR (1) KR100785718B1 (en)
CN (2) CN1307473A (en)
AT (1) ATE522220T1 (en)
AU (1) AU761879B2 (en)
CA (1) CA2330916C (en)
DK (1) DK1079824T3 (en)
IL (2) IL139307A0 (en)
NZ (2) NZ507791A (en)
RU (1) RU2244547C2 (en)
WO (1) WO1999059578A1 (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1079824T3 (en) * 1998-05-19 2011-11-21 Res Dev Foundation Triterpene compositions and methods for their use
DK2204186T3 (en) 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
EP1185281A1 (en) * 1999-06-02 2002-03-13 Oxford Natural Products PLC Combination of glucosamine with herbal extracts of tripterygium, ligustrum and erycibe
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
US8071654B2 (en) 2000-11-09 2011-12-06 Pace-Asciak Cecil R Inhibitors of thromboxane formation and action
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
JP2002322076A (en) * 2001-02-26 2002-11-08 Oji Paper Co Ltd Trypsin inhibitor
US6777004B1 (en) * 2001-03-30 2004-08-17 Council Of Scientific & Industrial Research Composition containing novel compound corniculatonin having antifungi properties and a process for preparing the same
US7736677B2 (en) 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US7727561B2 (en) * 2001-08-31 2010-06-01 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7524824B2 (en) * 2003-09-04 2009-04-28 Pacific Arrow Limited Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
KR100464063B1 (en) * 2001-11-21 2005-01-06 한국생명공학연구원 Triterpenoid compounds with apoptosis-inducing activity on cells
BR0107262B1 (en) * 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira INHALORY PHARMACEUTICAL COMPOSITION
EP1467755A1 (en) 2001-12-21 2004-10-20 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
TWI241916B (en) * 2001-12-28 2005-10-21 Jian-Shin Yang Method for producing nanometer of natural materials
AU2003229202A1 (en) 2002-05-28 2003-12-12 The Hospital For Sick Children Compositions comprising hepoxilin analogs and their use in the treatment of cancer
CA2536604A1 (en) * 2002-08-30 2004-03-11 Biopharmacopae Design International Inc. Plant extracts for treatment of angiogenesis and metastasis
US7407675B2 (en) * 2002-12-27 2008-08-05 The Trustees Of Columbia University In The City Of New York Anti-neoplastic compositions comprising extracts of black cohosh
US20090186837A1 (en) * 2002-12-27 2009-07-23 The Trustees Of Columbia University In The City Of New York Anti-neoplastic compositions comprising extracts of black cohosh
US20090264377A1 (en) * 2002-12-27 2009-10-22 Linda Saxe Einbond Anti-neoplastic compositions comprising extracts of black cohosh
US7700745B2 (en) * 2003-02-28 2010-04-20 Japan Science And Technology Agency Method for separating carbohydrate in glycoside-linkage-having compound, carbohydrate separating system, carbohydrate separating reagent kit, standard sample for carbohydrate separation, and evaluation system
NZ546138A (en) * 2003-10-09 2009-12-24 Pacific Arrow Ltd Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US7488753B2 (en) * 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
US8614197B2 (en) * 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US20050095209A1 (en) * 2003-10-31 2005-05-05 Be! Products, Inc. Nail Application Containing Gotu Kola
US7388126B2 (en) * 2003-12-19 2008-06-17 Monsanto Technology Llc Use of nitric oxide modulators in Agrobacterium-mediated plant transformation
US9382285B2 (en) 2004-09-07 2016-07-05 Pacific Arrow Limited Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells
US8735558B2 (en) * 2005-02-14 2014-05-27 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
JP4488852B2 (en) * 2004-09-17 2010-06-23 味の素ゼネラルフーヅ株式会社 Composition having body fat reducing action
WO2006034345A2 (en) * 2004-09-20 2006-03-30 Research Development Foundation Avicin-coated stents
US7727401B2 (en) * 2004-11-09 2010-06-01 Air Products And Chemicals, Inc. Selective purification of mono-terpenes for removal of oxygen containing species
CA2629529A1 (en) * 2004-11-18 2006-05-26 Biopharmacopae Design International Inc. Plant extracts and dermatological uses thereof
US20090018146A1 (en) * 2005-01-27 2009-01-15 Research Development Corporation Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors
WO2006094267A2 (en) * 2005-03-03 2006-09-08 Indiana University Research And Technology Corporation Permethylation of oligosaccharides
US7536962B2 (en) * 2005-04-19 2009-05-26 Kamterter Ii, L.L.C. Systems for the control and use of fluids and particles
US7311050B2 (en) * 2005-04-19 2007-12-25 Kamterter Ii, L.L.C. Systems for the control and use of fluids and particles
US8308075B2 (en) 2005-04-19 2012-11-13 Kamterter Products, Llc Systems for the control and use of fluids and particles
US8586719B2 (en) * 2005-04-27 2013-11-19 Pacific Arrow Limited Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
PT1889065E (en) * 2005-05-18 2013-09-27 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US8853168B2 (en) * 2005-07-18 2014-10-07 Duke University Compositions for the reversible thioesterification of signaling proteins and methods of using same
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US20080103746A1 (en) 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
WO2007086100A1 (en) * 2006-01-24 2007-08-02 Ajinomoto General Foods, Inc. Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same
WO2007101202A1 (en) * 2006-02-27 2007-09-07 Research Development Foundation Cell-targeted ikb and methods for the use thereof
US8710252B2 (en) 2006-04-19 2014-04-29 Cecil Pace-Asciak Hepodxilin analog enantiomers
US20070264298A1 (en) * 2006-05-10 2007-11-15 Stephen W. Lee Harvestwinner
JP4771882B2 (en) * 2006-07-21 2011-09-14 味の素ゼネラルフーヅ株式会社 Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same
AU2007281037B2 (en) 2006-08-03 2012-11-15 Oncology Research International Limited Methods and compositions for promoting activity of anti-cancer therapies
US20090263349A1 (en) * 2006-08-03 2009-10-22 Michael John Story Methods and compositions for inhibiting angiogenesis
WO2008045955A2 (en) * 2006-10-10 2008-04-17 Mayo Foundation For Medical Education And Research Inhibiting cyclin d polypeptides
US20090105203A1 (en) * 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
DE102006061517A1 (en) * 2006-12-18 2008-06-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Angioinhibin
WO2008094873A1 (en) * 2007-01-29 2008-08-07 Ligums John E Therapeutic bph composition
US20090274722A1 (en) * 2007-01-29 2009-11-05 Ligums John E Therapeutic Composition for the Treatment of BPH and ED
KR101163215B1 (en) 2007-05-26 2012-07-06 한국생명공학연구원 Composition comprising an extract of Tiarella polyphylla or Triterpene compound isolated therefrom for preventing and treating cancer diseases
US20090068325A1 (en) * 2007-09-10 2009-03-12 Gil Depicciotto Method of treatment of fresh produce
US7795311B2 (en) * 2007-10-15 2010-09-14 Pittsburg State University Methods and compositions for the management of soil-borne fungal diseases
CN101167787B (en) * 2007-10-17 2011-06-22 江南大学 Albizzia plant extraction composition for inhibiting angiogenesis and preparation and application thereof
WO2009102375A2 (en) * 2007-11-26 2009-08-20 Research Development Foundation Use of avicins to deliver therapeutic and diagnostic agents
CA2721072A1 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
US20120277308A1 (en) 2010-07-16 2012-11-01 Pacific Arrow Limited compounds for treating cancer and other diseases
US9499577B2 (en) 2009-07-16 2016-11-22 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
US9434677B2 (en) 2009-07-16 2016-09-06 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
WO2011034591A1 (en) * 2009-09-17 2011-03-24 New York University Methods of blocking ultraviolet radiation and promoting skin growth using terpenes and terpenoids
WO2011080579A2 (en) * 2009-12-30 2011-07-07 Himalaya Global Holdings Limited A herbal composition for inflammatory disorders
US8698496B2 (en) * 2010-09-20 2014-04-15 The General Hospital Corporation Method for two-dimensional correlation magnetic resonance spectroscopy
PL2624702T3 (en) 2010-10-06 2016-09-30 Anti-biofilm compositions and methods for using
EP2529633B1 (en) * 2011-06-01 2014-08-06 Symrise AG Orally consumed preparations comprising particular sweet tasting triterpenes and triterpene glycosides
US10226435B2 (en) 2011-06-07 2019-03-12 New York University Compositions and methods for restoring the stratum corneum and treating dermatological diseases
EP2723357A4 (en) 2011-06-21 2015-04-01 Bvw Holding Ag Medical device comprising boswellic acid
US20130269537A1 (en) 2012-04-16 2013-10-17 Eugenio Minvielle Conditioning system for nutritional substances
US9175030B2 (en) 2012-02-24 2015-11-03 Jordan Gutterman Derivatives of avicin D and methods of making and using thereof
US8490862B1 (en) 2012-04-16 2013-07-23 Eugenio Minvielle Transformation system for nutritional substances
US20130269538A1 (en) 2012-04-16 2013-10-17 Eugenio Minvielle Transformation system for nutritional substances
US10219531B2 (en) 2012-04-16 2019-03-05 Iceberg Luxembourg S.A.R.L. Preservation system for nutritional substances
US9541536B2 (en) 2012-04-16 2017-01-10 Eugenio Minvielle Preservation system for nutritional substances
US9080997B2 (en) 2012-04-16 2015-07-14 Eugenio Minvielle Local storage and conditioning systems for nutritional substances
US9121840B2 (en) 2012-04-16 2015-09-01 Eugenio Minvielle Logistic transport system for nutritional substances
US9069340B2 (en) 2012-04-16 2015-06-30 Eugenio Minvielle Multi-conditioner control for conditioning nutritional substances
US9016193B2 (en) 2012-04-16 2015-04-28 Eugenio Minvielle Logistic transport system for nutritional substances
US9436170B2 (en) 2012-04-16 2016-09-06 Eugenio Minvielle Appliances with weight sensors for nutritional substances
US9702858B1 (en) 2012-04-16 2017-07-11 Iceberg Luxembourg S.A.R.L. Dynamic recipe control
US9072317B2 (en) 2012-04-16 2015-07-07 Eugenio Minvielle Transformation system for nutritional substances
US20140069838A1 (en) 2012-04-16 2014-03-13 Eugenio Minvielle Nutritional Substance Label System For Adaptive Conditioning
US8733631B2 (en) 2012-04-16 2014-05-27 Eugenio Minvielle Local storage and conditioning systems for nutritional substances
US9171061B2 (en) 2012-04-16 2015-10-27 Eugenio Minvielle Local storage and conditioning systems for nutritional substances
US9460633B2 (en) 2012-04-16 2016-10-04 Eugenio Minvielle Conditioner with sensors for nutritional substances
US9528972B2 (en) 2012-04-16 2016-12-27 Eugenio Minvielle Dynamic recipe control
US8550365B1 (en) 2012-04-16 2013-10-08 Eugenio Minvielle System for managing the nutritional content for nutritional substances
US9429920B2 (en) 2012-04-16 2016-08-30 Eugenio Minvielle Instructions for conditioning nutritional substances
US9414623B2 (en) 2012-04-16 2016-08-16 Eugenio Minvielle Transformation and dynamic identification system for nutritional substances
US9564064B2 (en) 2012-04-16 2017-02-07 Eugenio Minvielle Conditioner with weight sensors for nutritional substances
US8851365B2 (en) * 2012-04-16 2014-10-07 Eugenio Minvielle Adaptive storage and conditioning systems for nutritional substances
US20140179624A1 (en) 2012-12-20 2014-06-26 Research Development Foundation Cytoprotective derivatives of avicin d and methods of making and using thereof
CN104147088A (en) * 2013-05-15 2014-11-19 伽蓝（集团）股份有限公司 Application of opopanax extractive in aging prevention
CN104147089A (en) * 2013-05-15 2014-11-19 伽蓝（集团）股份有限公司 Opopanax extract, preparation method and application thereof
TWI492751B (en) * 2013-06-04 2015-07-21 Univ Kaohsiung Medical Pharmaceutical composition prepared from saikosaponin, the use and the preparation method thereof
US10790062B2 (en) 2013-10-08 2020-09-29 Eugenio Minvielle System for tracking and optimizing health indices
KR101514145B1 (en) * 2013-10-14 2015-04-21 동의대학교 산학협력단 A composition comprising Machaerium cuspidatum extracts having anti-cancer activity
KR101523434B1 (en) * 2013-10-14 2015-05-27 동의대학교 산학협력단 A composition comprising Julbernardia globiflora extracts having anti-cancer activity
RU2562592C2 (en) * 2013-10-23 2015-09-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Дальневосточный государственный технический рыбохозяйственный университет" Method of obtaining oil extract from sea cucumbers, possessing biologically active properties (versions)
RU2562595C2 (en) * 2013-10-23 2015-09-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Дальневосточный государственный технический рыбохозяйственный университет" Production of product with biologically active properties from holothurians
RU2562581C1 (en) * 2014-01-29 2015-09-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Дальневосточный государственный технический рыбохозяйственный университет" Method of producing biologically active agent from sea cucumber, having general tonic and immunomodulating properties
CN105358220A (en) * 2014-06-03 2016-02-24 高雄医学大学 Composition prepared from saikosaponin, the use and the preparation method thereof
USD762081S1 (en) 2014-07-29 2016-07-26 Eugenio Minvielle Device for food preservation and preparation
CN105467059B (en) * 2015-12-30 2017-10-24 云南理想药业有限公司 A kind of quality determining method for the Chinese medicine composition for treating blood urine
WO2019055119A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Method and composition for treating viral infection
JP7201659B2 (en) 2017-07-26 2023-01-10 ツェーエルエル ヒェーミシェス・ラボラトーリウム・ドクター・クルト・リヒター・ゲーエムベーハー topical herbal composition
EP3434256A1 (en) 2017-07-26 2019-01-30 CLR-Chemisches Laboratorium Dr. Kurt Richter GmbH Topical herbal compositions
KR20200083969A (en) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. Methods and neuroprotective compositions for treating neurological conditions
CN110680818A (en) * 2018-07-06 2020-01-14 云南民族大学 Application of nerchinic acid in preparing analgesic
CN110089326A (en) * 2019-03-08 2019-08-06 贵州民族大学 A kind of adjuvant and the method using its raising masson pine disease-resistant performance
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
KR20220151038A (en) 2020-03-31 2022-11-11 피닉스 바이오테크놀러지 인코포레이티드. Compositions for preventing coronavirus infection
RU2745401C1 (en) * 2020-07-13 2021-03-24 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр "Институт биологии южных морей имени А.О. Ковалевского РАН" (ФИЦ ИнБЮМ) Method for inducing the secretion of biologically active compounds in sea snail rapana venosa val.
CN111875662B (en) * 2020-08-19 2022-08-16 中国人民解放军空军军医大学 Extraction method and application of clematis midriflora stem chemical extract
CN112245416A (en) * 2020-11-17 2021-01-22 广西馨海药业科技有限公司 Application of pinnatifone A in preparation of drugs with sedative and hypnotic effects and drug composition
CN115843692B (en) * 2022-12-29 2023-09-29 浙江省农业科学院 Tissue culture method for allium fistulosum

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3070623A (en) 1957-07-16 1962-12-25 Biorex Laboratories Ltd Pharmacological compounds
US3070624A (en) 1960-03-04 1962-12-25 Biorex Laboratories Ltd Glycyrrhetinic acid dialkylaminoalkyl esters
GB1255098A (en) 1969-07-28 1971-11-24 Biorex Laboratories Ltd Derivatives of glycyrrhetinic acid
US3814766A (en) 1971-11-03 1974-06-04 Pfizer 11-deoxoglycyrrhetinic acid piperazides useful as antiulcer agents
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4526714A (en) 1982-12-13 1985-07-02 Cordis Europa N.V. Conjugates of anticoagulant and protein
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5183756A (en) 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
EP0484403A4 (en) 1989-07-27 1993-03-17 Univax Biologics Incorporated Lipid a analog/immunogenic carrier conjugates and the use thereof as vaccines
US5242813A (en) 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
JPH0673084A (en) * 1992-08-27 1994-03-15 Shiratori Seiyaku Kk Glycoside and antihepatitic agent comprising the same
PT679088E (en) 1992-09-29 2002-12-31 Inhale Therapeutic Syst PULMONARY ADMINISTRATION OF ACTIVE FRAGMENTS OF PARTIROID HORMONE
JP3222672B2 (en) * 1993-12-16 2001-10-29 三井農林株式会社 Protein synthesis inhibitor
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
KR0164266B1 (en) 1996-02-22 1999-01-15 오오니시 쿠니히로 Metabolites of ginseng saponins by human intestinal bacteria and its preparation for an anticancer
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
ES2333069T3 (en) 1997-03-10 2010-02-16 Ottawa Hospital Research Institute USE OF NUCLEIC ACIDS CONTAINING NON-METHYLED CPG DINUCLEOTIDE IN COMBINATION WITH ALUMINUM AS AN ASSISTANT.
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DK1079824T3 (en) * 1998-05-19 2011-11-21 Res Dev Foundation Triterpene compositions and methods for their use

Similar Documents

Publication Publication Date Title
RU2000131681A (en) Triterpene compositions and methods for their use
CA2330916A1 (en) Triterpene compositions and methods for use thereof
Bajracharya Diversity, pharmacology and synthesis of bergenin and its derivatives: Potential materials for therapeutic usages
US8859012B2 (en) Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
US8334269B2 (en) Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
KR101717301B1 (en) Process for extracting cardiac glycodides and compositions
CN101553497B (en) Anti-tumor compounds for inhibiting cancer growth
US20090156515A1 (en) Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
Magalhães et al. In vitro and in vivo antiproliferative activity of Calotropis procera stem extracts
US7138428B2 (en) Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same
EP1388542B1 (en) Use of hederagenin 3-O-alpha-L-rhamnopyranosyl((1->2)-[beta-D-glucopyranosyl(1->4)]-alpha-L-arabinopyranoside or an extract from Pulsatillae radix containing the same as a therapeutic agent for solid tumors
EP0792148B1 (en) Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity
KR100205045B1 (en) Novel triterpene glycosidic compound process thereof
Chatterjee et al. Chemical characterization of the flavonoid constituents of Cuscuta reflexa
JP2006225359A (en) Bleaching cosmetic
EP1619195A2 (en) Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same
US20090186835A1 (en) Treatment and prophylaxis of cancer
CN109265511B (en) Triterpenoid, preparation method thereof and application thereof in preparation of anti-cancer drugs
US4652636A (en) Pentene-diphenyl-diglucoside containing compound
KR102070721B1 (en) A pharmaceutical composition comprising compounds isolated from Agrimonia pilosa for preventing or treating cancer
CN105712982B (en) Dihydro- β -agarofuran type sesquiterpenoids, preparation method and application thereof
Falodun et al. Smooth muscle relaxant evaluation of Jatropha curcas Linn (Euphorbiaceae) and isolation of triterpenes
Tsepaeva et al. Bifunctionalized Betulinic Acid Conjugates with C-3-Monodesmoside and C-28-Triphenylphosphonium Moieties with Increased Cancer Cell Targetability
KR20010068837A (en) Anti-cancer agent containing masonone E from family Ulmaceae
CN106999530B (en) Methods and compositions for treating breast cancer